Barrick Mining Corporation Stock Price, News & Analysis

B (Barrick) completed the divestiture of its interests in the Tongon gold mine and certain exploration properties in Côte d’Ivoire to Atlantic Group for total consideration of up to $305 million.

The consideration comprises $192 million in cash (which includes a $23 million shareholder loan repayment payable within six months of closing) and contingent cash payments up to $113 million tied to the price of gold over 2.5 years and resource conversions over 5 years.

Barrick (NYSE:B) announced its Board has authorized management to explore an initial public offering (IPO) of a subsidiary ("NewCo") that would hold Barrick’s North American gold assets.

NewCo would be anchored by Barrick’s joint venture interests in Nevada Gold Mines and Pueblo Viejo, plus the wholly owned Fourmile discovery in Nevada. The IPO is contemplated as a listing of a small minority interest while Barrick intends to retain a significant controlling majority. The Board authorized exploration through early 2026 and the company will update progress at its Full Year 2025 Results in February 2026. Any IPO decision remains subject to Board approval, customary requirements, and market conditions.

B (Barrick) completed the divestiture of the Hemlo Gold Mine in Canada to Carcetti Capital Corp., which will be renamed Hemlo Mining Corp (HMC), for total consideration of up to $1.09 billion.

Transaction proceeds included $875 million in cash received on closing, $50 million in HMC shares received on closing, and a production and tiered gold price-linked cash payment structure of up to $165 million payable over a five-year term starting in January 2027. The company acknowledged cooperation from the Biigtigong Nishnaabeg and Netmizaaggamig Nishnaabeg First Nations.

Barrick (NYSE:B) announced on November 26, 2025 that Ben van Beurden has stepped down as a director and as Lead Independent Director. Loreto Silva, an existing non-executive director, will succeed him as Lead Independent Director. The chairman said the board is focused on delivering long-term value and described the company as having industry-leading assets and a strengthened leadership team aligned on strategic priorities.

Barrick (NYSE:B) announced on November 24, 2025 that it has reached an agreement with the Government of the Republic of Mali to end disputes over the Loulo and Gounkoto mines.

Under the agreement, all charges against Barrick, its affiliates and employees will be dropped, the legal steps to secure the release of four detained Barrick employees will be taken, and the provisional administration of the Loulo-Gounkoto complex will be terminated, returning operational control to Barrick. Barrick subsidiaries will also withdraw ICSID arbitration claims, enabling a constructive path forward.

Crawford & Company (NYSE: CRD-A and CRD-B) announced a leadership transition: CEO Rohit Verma will step down effective December 31, 2025, and CFO W. Bruce Swain Jr. will become interim president & CEO and board member effective January 1, 2026. Holly Boudreau will succeed Swain as CFO effective January 1, 2026. Swain brings more than 30 years at Crawford and will focus on executing strategic plans and empowering employees. Verma served as CEO since May 2020 and joined Crawford in 2017. The company describes the transition as occurring from a position of financial strength with a global leadership team in place.

BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.

Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.

BioArctic (NASDAQ: B) partner Eisai received MHRA approval in the United Kingdom for Leqembi (lecanemab) as a once-every-four-weeks IV maintenance treatment for early Alzheimer’s disease on November 14, 2025.

After an initial 18-month induction of 10 mg/kg every two weeks, patients may be transitioned to 10 mg/kg every four weeks or remain on the two-week schedule. Leqembi previously received a UK approval in August 2024 for treatment of MCI and mild dementia due to Alzheimer’s in ApoE ε4 heterozygotes and non-carriers. BioArctic and Eisai are preparing joint commercialization in the Nordic region, where BioArctic holds commercialization rights.

Inertial Sense (B) agreed to be acquired by Hexagon AB (HEXA B), strengthening Hexagon’s assured Positioning, Navigation, and Timing (PNT) capabilities for autonomy, aerospace, and defense.

Under the agreement, Inertial Sense will join Hexagon’s Autonomous Solutions business area and continue operations there. Inertial Sense has shipped over 30,000 navigation systems worldwide and provides centimeter-level accuracy in compact GNSS+INS products. The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.